CD44 and cancer: Furthermore, we examined the in vitro targeting ability of the optimized HA/DOX nanoaggregates, the specific delivery of DOX into the nuclei of CD44-overexpressing cancer cells, and their anticancer effects against CD44-overexpressing cancer cells using annexin V staining and the transferase dUTP nick-end labeling (TUNEL) assay.